Research and Markets: USA Pharmaceutical Pricing & Reimbursement Concise Guide

DUBLIN--(BUSINESS WIRE)-- Research and Markets ( has announced the addition of the "IMS Pricing & Reimbursement Concise Guide: USA" report to their offering.

USA Pharmaceutical Pricing & Reimbursement Concise Guide

The P&R Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the IMS pricing and reimbursement specialists to provide industry players and decision makers with a thorough understanding of the rules and regulations governing P&R in international markets. This report covers key developments in P&R, market access, cost containment, trade margins and healthcare issues.

Key Topics Covered:

Healthcare System

  • Facts & Figures
  • Market Indicators
  • Provision & Funding


  • Prescription Drugs
  • Private Plans
  • Medicare Part B
  • Medicare Part D
  • Medicaid
  • Other Federal Programmes
  • Generic Drugs
  • Hospital Drugs
  • Otc Drugs


  • Admission to Reimbursement
  • Private Plans
  • Medicare Part B
  • Medicare Part D
  • Medicaid
  • Other Federal Programmes
  • Reimbursement Categories
  • Reimbursement Prices
  • Hospital Reimbursement
  • Formularies
  • Funding
  • Changes in Reimbursement Status
  • Changes in Reimbursement Prices


  • Pharmacoeconomic Requirements

Price Build Up

  • Wholesalers
  • Retail Pharmacies
  • Dispensing Doctors
  • Sales Tax

Cost Containment

  • Industry Paybacks
  • Promotional Costs
  • Patient Co-Payments
  • Private Plans
  • Medicare Part D
  • Medicaid
  • Prescribing Controls
  • Generics
  • Biosimilars
  • Rx-To-Otc Switches
  • Parallel Trade

Future Developments

  • Outlook

Names & Addresses

For more information visit

Source: IMS Health


Research and Markets
Laura Wood, Senior Manager
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   United States  North America

INDUSTRY KEYWORDS:   Health  Pharmaceutical



Suggested Articles

Esperion's Nexletol has had a rough road to approval after safety concerns nearly derailed its quest. But an FDA nod has the drug ready for market.

The FDA approved Lundbeck's Vyepti, formerly known as eptinezumab, as the first IV therapy to prevent migraines in adults.

In an interview with Israel's Calcalist, Teva CEO Kåre Schultz shared details of his approach to the company's turnaround.